Expanded Access for Relatlimab
- Registration Number
- NCT05170659
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
This is an expanded access designed to provide access to Relatlimab for eligible participants.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NO_LONGER_AVAILABLE
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the molecular mechanism of Relatlimab in combination with PD-1 inhibitors for immune checkpoint blockade?
How does Relatlimab compare to standard-of-care immunotherapies in terms of efficacy and safety for advanced melanoma?
Which biomarkers are associated with response to Relatlimab in patients with PD-L1 negative tumors?
What are the common adverse events of Relatlimab and nivolumab combination therapy and how are they managed in clinical practice?
Are there other LAG-3 inhibitors in development by Bristol-Myers Squibb or competitors for oncology indications?